abstract |
The present invention relates to compounds of the formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors. Ring A is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; which is optionally substituted. |